

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Alberta Children's Hospital, Calgary, Alberta, Canada

University of Alberta Hospital, Edmonton, Alberta, Canada

Vancouver General Hospital, Vancouver, British Columbia, Canada

University of Manitoba, Winnipeg, Manitoba, Canada

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, Canada

Kingston General Hospital, Kingston, Ontario, Canada

London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

The Hospital for Sick Children, Toronto, Ontario, Canada

The Fred A. Litwin Family Centre in Genetic Medicine, Toronto, Ontario, Canada

Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada

Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada

The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients with Fabry disease.